Back

Plasma fibroblast growth factor 23 is associated with poor outcome and unsuccessful uptitration of guideline-recommended pharmacotherapy in patients with worsening heart failure

22 May 2016 (11:00 - 11:15)
Organised by:
Congress Presentation Part of: Young Investigator Award: Clinical Prognosis (using biomarkers) HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Assistant Professor Jozine Ter Maaten

University Medical Centre Groningen, Groningen (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Prognostic burden of heart failure diagnosed in primary care or secondary care: a population-based linked electronic health record cohort study in 2.1 million people
Doctor S. Koudstaal (Gouda, NL)
Abstract Slides Video
Presentation thumbnail
Treatment with insulin increases mortality in diabetic patients with chronic heart failure: data from the GISSI-HF Trial.
Doctor D. Cosmi (Perugia, IT)
Abstract Slides Video
Presentation thumbnail
Genetic screening in dilated and non-dilated cardiomyopathy: should we broaden our perspective?
Mr M. Hazebroek (Maastricht, NL)
Abstract
Presentation thumbnail
Renal venous pattern: a new parameter for predicting cardiorenal syndrome progression
Doctor F. Monitillo (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
The metabolic exercise cardiac and kidney indexes (mecki) score: a new prognostic tool in patients with heart failure. a multicenter comparison with seattle and hfss in a large cohort of patients
Doctor M. Mapelli (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award: Clinical

The Event

Event poster

HEART FAILURE 2016

22 May 2016 11:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources